CHAPEL HILL, N.C., April 2, 2008 /PRNewswire/ -- Best-in-class pharmaceutical companies have begun to proactively protect their products throughout their value chain to mitigate the risk from counterfeit products. According to research by Best Practices, LLC, a leading pharmaceutical research firm.
Download a complimentary sample of this research, "Ensuring Brand & Health Safety from Parallel Importation and Counterfeits," at http://www3.best-in-class.com/br120.htm.
By confronting the problem by first examining brand security staffing
and funding, pharmaceutical companies can implement strategies that:
-- Prevent the introduction of counterfeit drugs and illegal parallel
imports into the U.S. drug distribution chain;
-- Facilitate the identification of such drugs;
-- Minimize the risk and exposure of consumers to counterfeit drugs and
-- Avoid unnecessary costs to the prescription drug distribution system
and unnecessary restrictions on lower-cost sources of drugs
"Ensuring Brand & Health Safety from Parallel Importation and Counterfeits" reflects the type of research Best Practices, LLC conducts for members of its Business Excellence Board (http://www3.best-in-class.com/beb), a research and advisory service for health care and pharmaceutical executives.
For information on other services by Best Practices, LLC and its Business Excellence Board, contact Cameron Tew at firstname.lastname@example.org or 919-403-0251, ext. 246.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved